BR112013002846A2 - derivados de tandospirona deuterada como agonista do receptor de 5-ht1a - Google Patents

derivados de tandospirona deuterada como agonista do receptor de 5-ht1a

Info

Publication number
BR112013002846A2
BR112013002846A2 BR112013002846A BR112013002846A BR112013002846A2 BR 112013002846 A2 BR112013002846 A2 BR 112013002846A2 BR 112013002846 A BR112013002846 A BR 112013002846A BR 112013002846 A BR112013002846 A BR 112013002846A BR 112013002846 A2 BR112013002846 A2 BR 112013002846A2
Authority
BR
Brazil
Prior art keywords
derivatives
deuterated
tandospirone
ht1a receptor
receptor agonist
Prior art date
Application number
BR112013002846A
Other languages
English (en)
Inventor
John Bondo Hansen
Mikael Sondergaard Thomsen
Original Assignee
Conrig Pharma Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conrig Pharma Aps filed Critical Conrig Pharma Aps
Publication of BR112013002846A2 publication Critical patent/BR112013002846A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

derivados de tandospirona deuterada como agonista do receptor de 5-ht1a. a presente invenção refere-se a novos derivados deuterados de agonistas do receptor de 5-ht1a de serotonina e em particular às composições e métodos para uso terapêuticos.
BR112013002846A 2010-08-05 2011-08-04 derivados de tandospirona deuterada como agonista do receptor de 5-ht1a BR112013002846A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201070349 2010-08-05
PCT/DK2011/050302 WO2012016569A1 (en) 2010-08-05 2011-08-04 Deuterated tandospirone derivatives as 5-ht1a receptor agonists

Publications (1)

Publication Number Publication Date
BR112013002846A2 true BR112013002846A2 (pt) 2016-06-07

Family

ID=44512475

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013002846A BR112013002846A2 (pt) 2010-08-05 2011-08-04 derivados de tandospirona deuterada como agonista do receptor de 5-ht1a

Country Status (5)

Country Link
US (1) US20130303497A1 (pt)
EP (1) EP2601187A1 (pt)
BR (1) BR112013002846A2 (pt)
MX (1) MX2013001234A (pt)
WO (1) WO2012016569A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013121440A1 (en) 2012-02-13 2013-08-22 Cadila Healthcare Limited Process for preparing benzisothiazol-3-yl-peperazin-l-yl-methyl-cyclo hexyl-methanisoindol-1,3-dione and its intermediates
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
IT201900000657A1 (it) 2019-01-16 2020-07-16 Procos Spa Processo per la sintesi di gepirone
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4507303A (en) 1981-12-22 1985-03-26 Sumitomo Chemical Company, Limited Succinimide derivatives, compositions and method of use
US5011841B1 (en) * 1989-11-14 1994-09-06 Pfizer Treatment of depression
US5330762A (en) 1992-02-27 1994-07-19 Alza Corporation Tandospiaine antidepressive therapy
JP2002020291A (ja) 2000-06-30 2002-01-23 Sumitomo Pharmaceut Co Ltd 認知機能障害の治療剤
JP2003335678A (ja) 2002-05-17 2003-11-25 Sumitomo Pharmaceut Co Ltd 神経因性疼痛治療薬
US20040002500A1 (en) 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
JP4677191B2 (ja) 2004-02-16 2011-04-27 あすか製薬株式会社 過敏性腸症候群処置剤
JPWO2005117886A1 (ja) 2004-06-01 2008-04-03 久光製薬株式会社 貼付剤
WO2008044336A1 (fr) 2006-10-11 2008-04-17 Hisamitsu Pharmaceutical Co., Inc. Préparation adhésive contenant un cristal
TW201023912A (en) 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension

Also Published As

Publication number Publication date
EP2601187A1 (en) 2013-06-12
US20130303497A1 (en) 2013-11-14
WO2012016569A1 (en) 2012-02-09
MX2013001234A (es) 2013-04-24

Similar Documents

Publication Publication Date Title
BR112013002846A2 (pt) derivados de tandospirona deuterada como agonista do receptor de 5-ht1a
CL2017000969A1 (es) Composiciones del factor viii y métodos para hacerlas y usarlas (divisional solicitud no. 2166-2014)
GT201500138A (es) Novedososo derivados de bencimidazol como antagonistas de ep4
CO6900118A2 (es) Métodos para tratar el cancer por el uso de antagonistas de unión al eje pd-1e inhibidores de mek
CO7160029A2 (es) Compuestos de heterociclilo como inhibidores de mek
HK1201260A1 (en) New indanyloxydihydrobenzofuranylacetic acid derivatives and their use as gpr40 receptor agonists gpr40
CO6831975A2 (es) Inmunoconjugados, composiciones para prepararlos, métodos para prepararlos y uso
BR112014014547A2 (pt) compostos antagonistas de e-selectina, composições e métodos de uso
BR112014011351A2 (pt) inibidores de acc e usos dos mesmos
UA111640C2 (uk) ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
GT201400086A (es) Compuestos con actividad nematicida
BR112014004557A2 (pt) compostos (tieno[2,3-b][1,5]benzoxazepin-4-il)piperazin-1-ila como agonistas inversos de h1/antagonistas de 5-ht2a de dupla atividade
MX2016001788A (es) Derivados de benzimidazolil-metil urea como agonistas del receptor de alx.
BR112015012746A2 (pt) compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos
ECSP14013215A (es) Compuestos novedosos
BR112013021991A8 (pt) composições com base em filossilicatos e métodos de fabricação das mesmas, para pirólise catalítica de biomassa
BR112015012730A2 (pt) compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos
CL2012003681A1 (es) Compuestos derivados de piperidina; composicion farmaceutica; y su uso como inhibidores de acetil-coa carboxilasa para el tratamiento de trastornos metabolicos, tales como obesidad y diabetes.
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
CL2014003059A1 (es) Uso de seaprose para eliminar biopelículas bacterianas; composicion de seaprose.
CR20140257A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
MX2013009259A (es) Dispersiones oleosas de agroquimicos estables.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]